132 related articles for article (PubMed ID: 9826708)
1. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.
Bardelli A; Longati P; Gramaglia D; Basilico C; Tamagnone L; Giordano S; Ballinari D; Michieli P; Comoglio PM
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14379-83. PubMed ID: 9826708
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
3. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
4. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
5. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
6. Activating mutations for the met tyrosine kinase receptor in human cancer.
Jeffers M; Schmidt L; Nakaigawa N; Webb CP; Weirich G; Kishida T; Zbar B; Vande Woude GF
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11445-50. PubMed ID: 9326629
[TBL] [Abstract][Full Text] [Related]
7. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth.
Bardelli A; Longati P; Williams TA; Benvenuti S; Comoglio PM
J Biol Chem; 1999 Oct; 274(41):29274-81. PubMed ID: 10506185
[TBL] [Abstract][Full Text] [Related]
8. A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
Giordano S; Bardelli A; Zhen Z; Menard S; Ponzetto C; Comoglio PM
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13868-72. PubMed ID: 9391119
[TBL] [Abstract][Full Text] [Related]
9. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
[TBL] [Abstract][Full Text] [Related]
10. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
Chiara F; Michieli P; Pugliese L; Comoglio PM
J Biol Chem; 2003 Aug; 278(31):29352-8. PubMed ID: 12746450
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
13. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms.
Maritano D; Accornero P; Bonifaci N; Ponzetto C
Oncogene; 2000 Mar; 19(10):1354-61. PubMed ID: 10713677
[TBL] [Abstract][Full Text] [Related]
14. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
15. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
16. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
17. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
Olivero M; Valente G; Bardelli A; Longati P; Ferrero N; Cracco C; Terrone C; Rocca-Rossetti S; Comoglio PM; Di Renzo MF
Int J Cancer; 1999 Aug; 82(5):640-3. PubMed ID: 10417759
[TBL] [Abstract][Full Text] [Related]
18. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
19. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation.
Buckwalter TL; Venkateswaran A; Lavender M; La Perle KM; Cho JY; Robinson ML; Jhiang SM
Oncogene; 2002 Nov; 21(53):8166-72. PubMed ID: 12444552
[TBL] [Abstract][Full Text] [Related]
20. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
Peace BE; Hughes MJ; Degen SJ; Waltz SE
Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]